PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

BRAF inhibitors (BRAFi) selectively target oncogenic BRAF(V600E/K) and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecular proce...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Sci Rep
Glavni autori: Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155038/
https://ncbi.nlm.nih.gov/pubmed/34040017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89389-9
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items